ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för Galeterone. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

13 träffar

Bibliografisk träff 2024-03-21

Structure-Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer.

Xiao M, Ha S, Zhu J, Tao W, Fu Z, Wei H, Hou Q, Luo G, Xiang H.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c02177

Bibliografisk träff 2023-07-17

Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer.

Wang A, Luo X, Meng X, Lu Z, Chen K, Yang Y.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c00880

Bibliografisk träff 2023-01-13

A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor.

Peřina M, Kiss MA, Mótyán G, Szczyrbová E, Eliáš M, Študent V, Kurfürstová D, Kovalová M, Mada L, Bouchal J, Frank É, Jorda R.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115086

Bibliografisk träff 2022-12-02

A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives.

Ha S, Luo G, Xiang H.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.2c01487

Bibliografisk träff 2022-09-07

Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.

Wang A, Luo X, Wang Y, Meng X, Lu Z, Yang Y.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c01164

Bibliografisk träff 2019-06-18

Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.

Jorda R, Řezníčková E, Kiełczewska U, Maj J, Morzycki JW, Siergiejczyk L, Bazgier V, Berka K, Rárová L, Wojtkielewicz A.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.06.040

Bibliografisk träff 2019-05-30

Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.

Jorda R, Lopes SMM, Řezníčková E, Ajani H, Pereira AV, Gomes CSB, M V D Pinho E Melo T.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.05.064

Bibliografisk träff 2019-03-22

Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.

Yu J, Zhang L, Yan G, Zhou P, Cao C, Zhou F, Li X, Chen Y.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.03.041

Bibliografisk träff 2018-05-24

Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.

Fehl C, Vogt CD, Yadav R, Li K, Scott EE, Aubé J.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.8b00419

Bibliografisk träff 2017-11-02

Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.

Romero-Hernández LL, Merino-Montiel P, Meza-Reyes S, Vega-Baez JL, López Ó, Padrón JM, Padrón JM, Montiel-Smith S.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2017.10.063

Bibliografisk träff 2016-05-23

Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.

Purushottamachar P, Kwegyir-Afful AK, Martin MS, Ramamurthy VP, Ramalingam S, Njar VC.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.6b00137

Bibliografisk träff 2015-01-28

Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.

Njar VC, Brodie AM.

J Med Chem · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1021/jm501239f

Bibliografisk träff 2013-06-07

Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.

Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jm400048v